Compare SHASUN PHARMA with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA IPCA LABS SHASUN PHARMA/
IPCA LABS
 
P/E (TTM) x 123.9 22.8 542.9% View Chart
P/BV x 8.5 4.4 192.8% View Chart
Dividend Yield % 0.2 0.1 219.9%  

Financials

 SHASUN PHARMA   IPCA LABS
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
IPCA LABS
Mar-18
SHASUN PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs94695 13.5%   
Low Rs46400 11.4%   
Sales per share (Unadj.) Rs214.2260.2 82.3%  
Earnings per share (Unadj.) Rs5.319.0 28.1%  
Cash flow per share (Unadj.) Rs15.833.1 47.9%  
Dividends per share (Unadj.) Rs1.001.00 100.0%  
Dividend yield (eoy) %1.40.2 783.5%  
Book value per share (Unadj.) Rs53.3213.0 25.0%  
Shares outstanding (eoy) m56.62126.20 44.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.1 15.5%   
Avg P/E ratio x13.128.9 45.4%  
P/CF ratio (eoy) x4.416.6 26.7%  
Price / Book Value ratio x1.32.6 51.0%  
Dividend payout %18.75.3 355.5%   
Avg Mkt Cap Rs m3,95869,120 5.7%   
No. of employees `000NA13.3 0.0%   
Total wages/salary Rs m2,1647,359 29.4%   
Avg. sales/employee Rs ThNM2,477.4-  
Avg. wages/employee Rs ThNM555.2-  
Avg. net profit/employee Rs ThNM180.6-  
INCOME DATA
Net Sales Rs m12,12732,836 36.9%  
Other income Rs m229418 54.9%   
Total revenues Rs m12,35633,254 37.2%   
Gross profit Rs m1,0094,505 22.4%  
Depreciation Rs m5941,777 33.4%   
Interest Rs m415240 172.8%   
Profit before tax Rs m2302,905 7.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-73511 -14.2%   
Profit after tax Rs m3022,394 12.6%  
Gross profit margin %8.313.7 60.7%  
Effective tax rate %-31.717.6 -180.0%   
Net profit margin %2.57.3 34.2%  
BALANCE SHEET DATA
Current assets Rs m6,88419,455 35.4%   
Current liabilities Rs m8,45610,076 83.9%   
Net working cap to sales %-13.028.6 -45.4%  
Current ratio x0.81.9 42.2%  
Inventory Days Days6298 63.0%  
Debtors Days Days10867 160.6%  
Net fixed assets Rs m4,97020,260 24.5%   
Share capital Rs m113252 44.9%   
"Free" reserves Rs m2,87526,633 10.8%   
Net worth Rs m3,02026,886 11.2%   
Long term debt Rs m1,8172,340 77.7%   
Total assets Rs m13,34741,173 32.4%  
Interest coverage x1.613.1 11.9%   
Debt to equity ratio x0.60.1 691.4%  
Sales to assets ratio x0.90.8 113.9%   
Return on assets %5.46.4 84.0%  
Return on equity %10.08.9 112.3%  
Return on capital %13.310.8 123.8%  
Exports to sales %46.447.6 97.3%   
Imports to sales %14.214.9 95.8%   
Exports (fob) Rs m5,62215,642 35.9%   
Imports (cif) Rs m1,7284,884 35.4%   
Fx inflow Rs m5,84315,642 37.4%   
Fx outflow Rs m2,1734,884 44.5%   
Net fx Rs m3,66910,759 34.1%   
CASH FLOW
From Operations Rs m3983,411 11.7%  
From Investments Rs m-1,635-1,354 120.8%  
From Financial Activity Rs m1,309-1,304 -100.3%  
Net Cashflow Rs m71753 9.5%  

Share Holding

Indian Promoters % 39.2 45.9 85.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 11.4 31.6%  
FIIs % 17.6 25.3 69.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 17.4 227.6%  
Shareholders   20,750 36,892 56.2%  
Pledged promoter(s) holding % 12.3 2.1 574.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA - NATCO PHARMA COMPARISON

COMPARE SHASUN PHARMA WITH

MARKET STATS